ArticleJACC. Advances2025
Improved Survival in Octogenarians With Heart Failure: 15-Year Cohort Study From a National Referral Center.
Article in JACC. Advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Uric Acid Variability Is Associated with Poor Prognosis in Heart Failure.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOctogenarians (aged ≥80 years) represent a significant subpopulation of heart failure (HF) patients yet remain underrepresented in clinical trials.
objectivesThis study evaluates trends in mortality among octogenarians with HF between 2009 and 2024.
methodsThis was a retrospective analysis of HF patients treated at a single tertiary center. The primary outcome was all-cause mortality. Kaplan-Meier survival analysis and Cox proportional hazards regression models were applied, stratifying patients by age (octogenarians or older and nonoctogenarians), by time period (before and after June 2016), HF type (heart failure with preserved [HFpEF] and reduced ejection fraction), and frailty status.
resultsAmong 32,892 patients (median age 72 years, IQR: 64-82; 58% [19,168] males), 11,013 (33%) were octogenarians or older. Over a 5-year median follow-up (IQR: 1-7), 18,558 (56%) died. Five-year mortality was 69% (7,599/11,013) in octogenarians or older vs 37% (8,095/21,879) in nonoctogenarians (P < 0.001). Use of guideline-directed medical therapy increased over time. Adjusted HRs for mortality in octogenarians or older, compared with nonoctogenarians, decreased between the early period (HR: 2.1; 95% CI: 2.03-2.19; P < 0.001) compared to the later period (HR: 1.6; 95% CI: 1.57-1.75; P < 0.001; P for interaction <0.001). In the overall cohort, mortality HR declined in HFpEF patients (HR: 2.02-1.62, P for interaction <0.001), but not in heart failure with reduced ejection fraction patients (HR: 2.25-2.00, P for interaction = 0.400). In the overall cohort, decreases in mortality HR between the early and late period were significant in nonfrail patients.
conclusionsOver a 15-year period, mortality risks among octogenarians and older with HF decreased, especially in HFpEF and nonfrail patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.